Krensavage Asset Management LLC
Michael Krensavage New York, NY 20 13Fs · since 2021 Q3
- AUM $256M
- positions 20
- period 2026 Q1
- QoQ −9.5%
- top 5 64.7%
- qoq N 5 E 3 A 4 R 4
- UNITED THERAPEUTICS CORP - UTHR 19.5%
- ENANTA PHARMACEUTICALS INC 14.2%
- JAZZ PHARMACEUTICALS PLC - JAZZ 12.4%
- BIOMARIN PHARMACEUTICAL INC - BMRN 11.6%
- EXELIXIS INC - EXEL 7.0%
- SANOFI-ADR - SNY 6.1%
- SUPERNUS PHARMACEUTICALS INC 5.7%
- INDIVIOR PHARMACEUTICALS INC - INDV 4.0%
- ULTRAGENYX PHARMACEUTICAL IN 3.2%
- VANDA PHARMACEUTICALS INC 3.2%
- EMBECTA CORP 2.5%
- GSK PLC-SPON ADR - GSK 2.1%
- Other 8.5%
AUM over time
Holdings value
Latest book
| UNITED THERAPEUTICS CORP - UTHR | 19.55% | Reduce −7.7% | 84,282 | $592.99 | $50M | −7,000 | +$6M |
| ENANTA PHARMACEUTICALS INC | 14.16% | Add +3.6% | 2,866,138 | $12.63 | $36M | +99,748 | −$7M |
| JAZZ PHARMACEUTICALS PLC - JAZZ | 12.41% | 167,816 | $189.05 | $32M | — | — | |
| BIOMARIN PHARMACEUTICAL INC - BMRN | 11.59% | 524,786 | $56.49 | $30M | — | — | |
| EXELIXIS INC - EXEL | 6.97% | Reduce −15.8% | 415,693 | $42.89 | $18M | −77,833 | −$4M |
| SANOFI-ADR - SNY | 6.10% | 323,946 | $48.18 | $16M | — | — | |
| SUPERNUS PHARMACEUTICALS INC | 5.67% | Reduce −10.5% | 280,681 | $51.69 | $15M | −32,818 | −$1M |
| INDIVIOR PHARMACEUTICALS INC - INDV | 4.05% | New | 339,532 | $30.48 | $10M | +339,532 | +$10M |
| ULTRAGENYX PHARMACEUTICAL IN | 3.20% | Add +161.2% | 390,879 | $20.95 | $8M | +241,245 | +$5M |
| VANDA PHARMACEUTICALS INC | 3.19% | 1,180,388 | $6.91 | $8M | — | — | |
| EMBECTA CORP | 2.54% | New | 735,340 | $8.84 | $6M | +735,340 | +$6M |
| GSK PLC-SPON ADR - GSK | 2.09% | 96,729 | $55.19 | $5M | — | — | |
| BIONTECH SE-ADR - BNTX | 2.07% | Reduce −40.2% | 59,523 | $88.87 | $5M | −40,000 | −$4M |
| ALKERMES PLC | 1.49% | 107,822 | $35.36 | $4M | — | — | |
| BIOGEN INC - BIIB | 1.43% | Add +100.0% | 20,000 | $183.35 | $4M | +10,000 | +$2M |
| REGENERON PHARMACEUTICALS - REGN | 1.21% | 4,000 | $772.75 | $3M | — | — | |
| ARDELYX INC - ARDX | 1.17% | New | 500,000 | $5.99 | $3M | +500,000 | +$3M |
| INMODE LTD | 0.65% | New | 120,942 | $13.68 | $2M | +120,942 | +$2M |
| EVOLUS INC | 0.25% | Add +58.0% | 157,985 | $4.11 | $649 | +57,985 | −$16 |
| ABBOTT LABORATORIES - ABT | 0.20% | New | 5,000 | $102.60 | $513 | +5,000 | +$513 |
| AVADEL PHARMACEUTICALS | — | Exit | 0 | $21.55 | — | −855,860 | −$18M |
| CARDINAL HEALTH INC - CAH | — | Exit | 0 | $205.51 | — | −73,745 | −$15M |
| INDIVIOR PLC - INDV | — | Exit | 0 | $35.88 | — | −339,532 | −$12M |
* Reported price is value ÷ shares from the 13F as of period end — not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q4. Click column headers to sort · click New / Exit / Add / Reduce to promote that move type to the top. Among managers we track.
filings history
20 periods · normalized AUM · click period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q1 | 20 | $256M | −9.5% | 13F-HR | 5/15/2026 | 000160925126000004 |
| 2025 Q4 | 18 | $283M | +20.4% | 13F-HR | 2/18/2026 | 000160925126000003 |
| 2025 Q3 | 17 | $235M | +24.3% | 13F-HR | 11/17/2025 | 000160925125000007 |
| 2025 Q2 | 15 | $189M | +4.4% | 13F-HR | 8/15/2025 | 000160925125000006 |
| 2025 Q1 | 14 | $181M | +7.1% | 13F-HR | 5/15/2025 | 000160925125000004 |
| 2024 Q4 | 12 | $169M | −5.1% | 13F-HR | 2/18/2025 | 000160925125000001 |
| 2024 Q4 | 12 | $169M | — | RESTATEMENT | 2/18/2025 | 000160925125000002 |
| 2024 Q3 | 13 | $178M | −18.3% | 13F-HR | 11/15/2024 | 000164227424000006 |
| 2024 Q2 | 13 | $218M | −3.5% | 13F-HR | 8/15/2024 | 000160925124000006 |
| 2024 Q1 | 12 | $226M | −19.9% | 13F-HR | 5/15/2024 | 000160925124000005 |
| 2023 Q4 | 12 | $282M | +3.7% | 13F-HR | 2/14/2024 | 000160925124000002 |
| 2023 Q3 | 12 | $272M | −13.9% | 13F-HR | 11/15/2023 | 000160925123000005 |
| 2023 Q2 | 12 | $316M | −4.0% | 13F-HR | 8/11/2023 | 000160925123000004 |
| 2023 Q1 | 12 | $329M | +1.5% | 13F-HR | 5/16/2023 | 000160925123000003 |
| 2022 Q4 | 12 | $324M | +3.2% | 13F-HR | 2/15/2023 | 000160925123000001 |
| 2022 Q3 | 14 | $314M | +4.0% | 13F-HR | 11/15/2022 | 000160925122000005 |
| 2022 Q2 | 14 | $302M | +4.1% | 13F-HR | 8/16/2022 | 000160925122000004 |
| 2022 Q1 | 13 | $290M | +0.7% | 13F-HR | 5/17/2022 | 000160925122000003 |
| 2021 Q4 | 10 | $288M | −9.7% | 13F-HR | 2/15/2022 | 000160925122000002 |
| 2021 Q3 | 13 | $319M | — | 13F-HR | 11/16/2021 | 000160925121000006 |
About
Krensavage Asset Management LLC
SEC: Krensavage Asset Management, LLC
20 processed 13Fs · since 2021 Q3